WO2008093076A3 - Assays and therapy - Google Patents

Assays and therapy Download PDF

Info

Publication number
WO2008093076A3
WO2008093076A3 PCT/GB2008/000305 GB2008000305W WO2008093076A3 WO 2008093076 A3 WO2008093076 A3 WO 2008093076A3 GB 2008000305 W GB2008000305 W GB 2008000305W WO 2008093076 A3 WO2008093076 A3 WO 2008093076A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
plasma
blood
vimentin
thrombosis
Prior art date
Application number
PCT/GB2008/000305
Other languages
French (fr)
Other versions
WO2008093076A2 (en
Inventor
Marlene Lydia Rose
Thomas J Podor
Original Assignee
Imp Innovations Ltd
Marlene Lydia Rose
Thomas J Podor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd, Marlene Lydia Rose, Thomas J Podor filed Critical Imp Innovations Ltd
Publication of WO2008093076A2 publication Critical patent/WO2008093076A2/en
Publication of WO2008093076A3 publication Critical patent/WO2008093076A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

A method for predicting or diagnosing thrombosis in a mammal, the method comprising detecting the presence and/or level of anti-vimentin antibodies in a suitable sample obtained from the mammal. Preferably the mammal is a human patient who has, or is at risk of having, thrombosis. A method of treating or preventing thrombosis in a patient, the method comprising administering to the patient a reagent that is selectively bound by anti-vimentin antibodies. Preferably, the reagent is vimentin. A method of treating or preventing thrombosis in a patient, the method comprising selectively removing anti-vimentin antibodies a patient's blood or plasma ex vivo, and returning the blood or plasma to the patient. A device for selectively removing anti-vimentin antibodies from the blood or plasma of a patient, the device comprising means for selectively removing anti- vimentin antibodies from blood or plasma; and inlet and outlet means for connection to a pump and tubing suitable for circulating the blood or plasma of the patient through the device.
PCT/GB2008/000305 2007-01-30 2008-01-30 Assays and therapy WO2008093076A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0701728.8 2007-01-30
GB0701728A GB0701728D0 (en) 2007-01-30 2007-01-30 Assays and therapy

Publications (2)

Publication Number Publication Date
WO2008093076A2 WO2008093076A2 (en) 2008-08-07
WO2008093076A3 true WO2008093076A3 (en) 2008-10-02

Family

ID=37873013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000305 WO2008093076A2 (en) 2007-01-30 2008-01-30 Assays and therapy

Country Status (2)

Country Link
GB (1) GB0701728D0 (en)
WO (1) WO2008093076A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0818614D0 (en) 2008-10-10 2008-11-19 Univ Dublin City Platelet Analysis
WO2017168014A1 (en) * 2016-04-02 2017-10-05 Protagen Ag Marker sequences for rheumatoid arthritis
US10695401B2 (en) 2016-12-01 2020-06-30 Baylor College Of Medicine Use of vimentin in the modulation of acute inflammation and thrombosis
CN112618712A (en) * 2021-01-21 2021-04-09 武汉轻工大学 Adjuvant containing vimentin and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHIRINOS J A ET AL: "Elevation of Endothelial Microparticles, Platelets, and Leukocyte Activation in Patients With Venous Thromboembolism", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 45, no. 9, 3 May 2005 (2005-05-03), pages 1467 - 1471, XP004872887, ISSN: 0735-1097 *
IKEDA HISAO ET AL: "Adhesive interaction between P-selectin and sialyl Lewisx plays an important role in recurrent coronary arterial thrombosis in dogs", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 4, April 1999 (1999-04-01), pages 1083 - 1090, XP002477907, ISSN: 1079-5642 *
JENSEN MORTEN KROGH ET AL: "Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count", EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 66, no. 3, March 2001 (2001-03-01), pages 143 - 151, XP002477905, ISSN: 0902-4441 *
KLINKHARDT UTE ET AL: "Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 71, no. 3, March 2002 (2002-03-01), pages 176 - 185, XP002477906, ISSN: 0009-9236 *
MCGREGOR LILIAN ET AL: "Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis", FRONTIERS IN BIOSCIENCE, vol. 11, January 2006 (2006-01-01), pages 830 - 837, XP002477904, ISSN: 1093-9946 *

Also Published As

Publication number Publication date
WO2008093076A2 (en) 2008-08-07
GB0701728D0 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2003069332A3 (en) Detection and/or monitoring of synuclein-related diseases
DE602005015894D1 (en) DIAGNOSTIC TEST APPARATUS
EP3708682A3 (en) Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
EP1905383A3 (en) Livestock foothbath system
WO2006086442A3 (en) Method of detecting abnormal tissue
WO2006073682A3 (en) Diagnostic test
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
EP3761034A3 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EP2177908A3 (en) Diabetes-associated markers and methods of use thereof
WO2010115621A3 (en) Device and method for measuring a blood constituent in blood for an extracorporeal blood treatment device
WO2008060777A3 (en) Elisa for vegf
BR112012026361A2 (en) therapy prediction and blood therapy optimization for renal failure, especially home hemodialysis
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP2006392A4 (en) METHOD FOR TESTING ALZHEIMER'S DISEASE BY ASSAYING DEGRADATION RATE OF beta-AMYLOID IN BLOOD AND DIAGNOSTIC REAGENT
WO2008093076A3 (en) Assays and therapy
BR112012031252A2 (en) blood cardiopulmonary bypass
WO2004088326A3 (en) Gastrin hormone immunoassays
WO2009043848A3 (en) Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions
Nakada et al. Blood purification for hypercytokinemia
WO2008015218A3 (en) Method for diagnosis of a disease involving an anti-at1-receptor antibody
ATE529743T1 (en) METHODS AND KITS FOR TUMORIGENICITY DIAGNOSIS
ATE336003T1 (en) METHOD FOR DIAGNOSIS OF SEPSIS BY DETERMINING ANTI-ASIALO-GANGLIOSIDE ANTIBODIES
EP1162457A3 (en) Multiple coagulation test system and method of using a multiple coagulation test system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701975

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701975

Country of ref document: EP

Kind code of ref document: A2